Omnicuris Logo
India's Parkinson's Surge: Why Young-Onset Cases are Rising

India's Parkinson's Surge: Why Young-Onset Cases are Rising

Read More
Full Text
3 months ago

India faces a major public health crisis due to a projected surge in Parkinson's disease India cases. Experts at the 6th International Annual Symposium-2026 in Kerala delivered a stark warning. They now expect India to become the country with the second-highest number of Parkinson's patients globally within five years. Ultimately, this alarming projection highlights a critical and growing neurological challenge for the nation. Consequently, the King's Parkinson's Research Alliance India (PRAI) symposium brought together global experts to discuss emerging challenges and innovative care.



Rising Burden of Young-Onset Parkinson's Disease India


Parkinson's disease is traditionally an older population ailment. However, symposium experts noted increasing diagnoses among younger individuals in Southeast Asia, including India. Therefore, the issue of young-onset Parkinson's (YOPD) is a known regional concern. This trend creates unique social, economic, and healthcare challenges for working-age patients. Furthermore, India’s current prevalence rate is 15-43 per 100,000. Experts project cases will increase significantly by 2030.


A significant portion of Indian cases are early-onset. Specifically, about 40 to 45% occur between the ages of 22 and 49. The average onset age is roughly 51 years. Doctors link the disease surge to several environmental and lifestyle factors. These include increased industrialisation, worsening air pollution, and changing lifestyles. Additionally, specific factors in North India—such as male gender, genetic history, and head injuries—show an association with a higher prevalence. This progressive neurodegenerative disorder, the second most common in adults over 60, demands enhanced public health policies.



Prioritizing Affordable Treatment and Research


Speakers at the symposium strongly emphasised the need for early diagnosis. Moreover, they called for region-specific research and affordable treatment options tailored to the Indian population. The event also highlighted emerging therapies and technological innovations set to transform Parkinson's treatment. Vinod Mehta, a Movement Disorders specialist, stressed the importance of empowering patients and caregivers. He stated that plenty of treatment options and novel therapies are now available.


King's College Hospital London, in collaboration with PRAI, is currently developing new technologies, like a treatment patch. This innovation must be made affordable through local manufacturing. Currently, patients sometimes pay ₹1 lakh per month for advanced treatments. Conversely, local manufacturing could potentially drop the cost to ₹1,000 per month, benefiting millions. International collaboration and supportive public health policies can dramatically reduce treatment costs. Additionally, researchers noted that Indian populations present a unique genetic landscape, including the p.Leu444Pro mutation, which is linked to earlier onset. Ultimately, long-term strategies require training healthcare professionals, strengthening research infrastructure, and increasing public awareness.



Frequently Asked Questions


Q1: Why is India expected to see a Parkinson's disease surge?


India is projected to become the country with the second-highest number of Parkinson's cases globally within five years. The surge is linked to factors like increased industrialisation, air pollution, changing lifestyles, and a high rate of young-onset cases.


Q2: What is the primary challenge regarding Parkinson's treatment affordability in India?


The high cost of advanced treatments, sometimes reaching ₹1 lakh per month, poses a major barrier to care. Experts believe local manufacturing of novel therapies, such as a new treatment patch, could reduce this cost to as low as ₹1,000 per month.


Q3: What percentage of Parkinson's cases in India are considered early-onset?


Approximately 40-45% of Indian cases are classified as early-onset, occurring in individuals between the ages of 22 and 49.



Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.



References



  1. India expected to see surge in Parkinson's disease, becoming 2nd-highest in 5yrs: Experts - ETHealthworld

  2. Surging Parkinson's disease in India worries global experts as youth cases rise across Southeast Asia - Prameya News

  3. India Likely to Have Highest Absolute Prevalence of Parkinson's Disease in the World, Says Experts - Amrita Hospital

  4. The Evolving Global Burden of Young-Onset Parkinson's Disease (1990-2021): Regional, Gender, and Age Disparities in the Context of Rising Incidence and Declining Mortality - PubMed

Login to continue

More from MedShots Daily

India's Parkinson's Surge: Why Young-Onset Cases are Rising
India's Parkinson's Surge: Why Young-Onset Cases are Rising

Experts warn that India will soon have the world's 2nd-highest number of Parkinson's disease cases, with a significant rise in young-onset PD linked to envi...

3 months ago

Read More
Full Text
Procizumab: A Novel Humanized Antibody for Neutralizing Circulating DPP3 in Shock
Procizumab: A Novel Humanized Antibody for Neutralizing Circulating DPP3 in Shock

Procizumab is a humanized antibody that neutralizes circulating DPP3, a biological driver of shock, by preventing angiotensin II degradation....

Today

Read More
Full Text
India Champions Global Maternal and Child Health Agenda
India Champions Global Maternal and Child Health Agenda

India offers technical support and proven digital public health solutions to advance maternal and child health outcomes globally....

Today

Read More
Full Text
India to Launch Registry for Implantable Medical Devices
India to Launch Registry for Implantable Medical Devices

India is launching a national registry to track implantable medical devices and patients, enhancing accountability and safety during global product recalls....

Today

Read More
Full Text
Medtronic Acquires SPR Therapeutics for $650 Million
Medtronic Acquires SPR Therapeutics for $650 Million

Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....

Today

Read More
Full Text
Sex-Specific Regulation of Juvenile Social Play by Oxytocin
Sex-Specific Regulation of Juvenile Social Play by Oxytocin

Research highlights sex-specific roles of oxytocin neurons in the hypothalamus and signaling in the nucleus accumbens regarding juvenile social play behavio...

Today

Read More
Full Text
Showing Page 1 of 1(5 items total)
Go to Page

"Wherever the art of Medicine is loved, there is also a love of Humanity."

— Hippocrates

made with❤️byOmnicuris